Lariosa-Willingham, Karen
Leonoudakis, Dmitri
Bragge, Timo
Tolppanen, Laura
Nurmi, Antti
Flanagan, Megan
Gibson, Janelle
Wilson, David
Stratton, Jennifer
Lehtimäki, Kimmo K.
Miszczuk, Diana
Funding for this research was provided by:
Teva Pharmaceutical Industries
Article History
Received: 30 July 2021
Accepted: 10 May 2022
First Online: 25 May 2022
Declarations
:
: All animal experiments were performed as specified in the license authorized by the National Animal Experiment Board of Finland and according to the National Institutes of Health (Bethesda, MD, USA) Guidelines for the Care and Use of Laboratory Animals.All animal experiments in this study were performed in accordance with the ARRIVE 2.0 guidelines.
: Teva Pharmaceuticals Industries Ltd. develops, produces and markets affordable, high quality generic drugs and specialty pharmaceuticals. Sword Diagnostics, Inc. develops next-generation biomarker detection technology. Charles River Discovery Services Finland Oy is a contract research organization that conducted part of the study through a fee-for-service agreement with Teva Pharmaceuticals Industries Ltd. At the time of the study, KKL, DM, TB, LT, and AN were employed by Charles River Discovery Services Finland Oy; KLW, DL, DW, JS were employed by Teva Pharmaceuticals Industries Ltd; MF and JG were employed by Sword Diagnostics, Inc.